Theravance has begun a dose ranging Phase 2b study of its TD-4208 inhalation solution in approximately 60 patients with moderate to severe COPD. According to the company, “The goal of Theravance’s LAMA program for respiratory disease is to develop a once-daily inhaled medicine in a nebulizer that offers improved efficacy and tolerability relative to current therapies and provides the basis for combination nebulized products with other medicines.”
Theravance Senior VP of Research and Early Clinical Development Mathai Mammen commented, “We are very pleased with the progression of TD-4208 into a Phase 2b study in patients with COPD. We believe that certain patients may prefer long-acting medicines delivered in the aqueous nebulized platform used in this study over handheld inhalation devices. In addition, TD-4208 may offer these patients the convenience of once-a-day dosing compared to currently nebulized medicines which must be dosed multiple times daily.”
Read the Theravance press release.
